Alliqua Biomedical (ALQA) 1.14 $ALQA
Four Penny Stocks To Watch Today, Friday, May 20
ACCESSWIRE - Fri May 20, 1:02PM CDT
MIAMI, FL / ACCESSWIRE / May 20, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch BBEP, RXMD, LNCO, andALQA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
LNCO: 0.12 (unch), BBEP: 0.13 (unch), ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. to Attend Craig-Hallum Institutional Investor Conference
GlobeNewswire - Mon May 16, 6:30AM CDT
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced that David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will attend the 13th Annual Craig-Hallum Institutional Investor Conference on Wednesday, June 1, 2016 at the Depot Renaissance Minneapolis Hotel in Minneapolis, MN.
ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Reports First Quarter Financial Results
GlobeNewswire - Tue May 10, 6:07AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced financial results for the first quarter ended March 31, 2016.
ALQA: 1.14 (-0.01)
Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 77.07 (+1.75), ANIP: 56.27 (+3.48), ANIK: 51.10 (+0.83), ALQA: 1.14 (-0.01)
Celgene Corporation (NASDAQ: CELG) CMO Joins MetaStat Inc (OTCQB: MTST) Board
ACCESSWIRE - Wed Apr 27, 9:26AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2016 / Development stage biotech company MetaStat Inc (OTCQB: MTST) just announced a high-profile, and potentially game changing addition to its board of directors. As of April 26, 2016, Jerome B. Zeldis, M.D., Ph.D, Chief Medical Officer of Celgene Corporation (NASDAQ:CELG) and Chief Executive Officer of Celgene Global Health, will join the Metastat board as its vice chairman. For a company the size of MetaStat, which had a market capitalization of a little over $3.42 million at last count, the addition of an industry professional with the standing of Zeldis is a validation of the potential of its lead diagnostics technology - something we will touch on in a little more detail shortly.
ALQA: 1.14 (-0.01), CELG: 100.66 (+1.43), CELGZ: 1.45 (+0.01)
Alliqua BioMedical, Inc. to Announce First Quarter of Fiscal Year 2016 Results on May 10th
GlobeNewswire - Tue Apr 26, 10:00AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced plans to release first quarter of fiscal year 2016 financial results before the market opens on May 10th.
ALQA: 1.14 (-0.01)
New Strong Buy Stocks for April 26th
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:40AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AXE: 60.65 (+1.15), ANIP: 56.27 (+3.48), APRI: 0.47 (-0.01), ALQA: 1.14 (-0.01), FLWS: 8.43 (+0.10)
Alliqua BioMedical Presents at the Spring 2016 SAWC Meeting
GlobeNewswire - Tue Apr 12, 6:30AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, will present new cytokine profile data from the analyses of wound fluid and tissue biopsies taken from venous leg ulcers at the Spring 2016 Symposium on Advanced Wound Care, being held at the Georgia World Congress Center in Atlanta, Georgia from April 13 - 17.
ALQA: 1.14 (-0.01)
Alliqua BioMedical to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Mar 30, 6:30AM CDT
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced that David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will attend the 15th Annual Needham Healthcare Conference in New York, New York.
ALQA: 1.14 (-0.01)
Medical Products Companies Tap Into $50 Billion U.S. Government GSA Supply Program
ACCESSWIRE - Wed Mar 16, 7:30AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 16, 2016 / Last week, BioLargo, Inc. (OTC: BLGO), best known for the AOS Filter that has demonstrated the highest impact and lowest cost of any known water treatment technology, announced that the U.S. government had awarded them a five-year General Services Administration and VA Schedule supply contract, under schedule 65IIA for medical equipment and supplies. This contract award is significant because it opens up an important selling channel for the company's current odor and moisture control products as well as future products that will include its Advanced Wound Care Products when they are approved by the FDA. The GSA Schedules program is the premier acquisition vehicle in government with approximately $50 Billion a year in spending for a broad spectrum of products.
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), VCEL: 2.29 (+0.06), ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Announces Participation in the Blue Cross Blue Shield Association's Evidence Street Pilot Program
GlobeNewswire - Tue Mar 15, 6:30AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced that the Company is now a member of the Blue Cross Blue Shield Association's ("BCBSA" Evidence Street Pilot Program, a program designed to create uniformity in the exchange of clinical evidence used to establish BCBSA clinical guidelines.
ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement Coverage for Biovance(R)
GlobeNewswire - Mon Mar 07, 6:30AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced that Biovance(R) Human Amniotic Membrane Allograft is now eligible for coverage in the geographic regions covered by Wisconsin Physicians Service ("WPS", a Medicare Administrative Contractor, or "MAC."
ALQA: 1.14 (-0.01)
Alliqua BioMedical Announces Changes to Its Board of Directors
GlobeNewswire - Fri Feb 19, 6:30AM CST
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company", today announced the appointment of Winston Kung to its Board of Directors. The Company also announced the departure of Perry Karsen from its Board of Directors.
AMGN: 152.27 (+2.46), ALQA: 1.14 (-0.01), CELGZ: 1.45 (+0.01)
Alliqua BioMedical, Inc. to Announce Fourth Quarter and Fiscal Year 2015 Results on February 23rd
GlobeNewswire - Tue Feb 09, 6:30AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced plans to release fourth quarter and fiscal year 2015 financial results before the market opens on February 23rd.
ALQA: 1.14 (-0.01)
Alliqua's UltraMIST(R) System Honored With GOOD DESIGN Award
GlobeNewswire - Thu Feb 04, 10:02AM CST
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company", today announced that its UltraMIST Ultrasound Healing Therapy System received a GOOD DESIGN(R) Award. The GOOD DESIGN Awards are presented by The Chicago Athenaeum Museum of Architecture and Design and the Metropolitan Arts Press Ltd to the world's leading designers to acknowledge creativity, modernization, advancement and outstanding products that stretch the boundaries of average design.
ALQA: 1.14 (-0.01)
Alliqua Biomedical Announces Partnership With Human Longevity Inc., Under Existing Licensing Agreement
GlobeNewswire - Thu Jan 28, 7:00AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced that following the completion of Human Longevity, Inc.'s ("HLI" planned purchase of LifebankUSA and other select assets from Celgene Cellular Therapeutics ("CCT", the Company will remain the exclusive commercial partner for the existing pipeline of human placental based products, including Biovance(R) Human Amniotic Membrane Allograft and CCT's connective tissue matrix product, which is pending commercial launch under its branded name, Interfyl(TM) Human Connective Tissue Matrix.
ALQA: 1.14 (-0.01), CELGZ: 1.45 (+0.01)
Alliqua BioMedical Announces Agreement With HealthTrust
GlobeNewswire - Wed Jan 27, 6:30AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announces that it has signed a national group purchasing agreement with HealthTrust. The agreement, which became effective on Jan. 1, 2016, added Alliqua's Biovance(R) Human Amniotic Membrane Allograft ("Biovance" to HealthTrust's regenerative tissue wound care contracting category.
ALQA: 1.14 (-0.01)
Direction of Market Influences - Research on Zion Oil and Gas, Alliqua Biomedical, MSB Financial and Profire Energy
ACCESSWIRE - Thu Dec 03, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Zion Oil and Gas Inc. (NASDAQ: ZN), Alliqua Biomedical Inc. (NASDAQ: ALQA), MSB Financial Corp. (NASDAQ: MSBF) and Profire Energy Inc. (NASDAQ: PFIE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ZN: 1.56 (+0.07), PFIE: 1.02 (+0.01), MSBF: 13.80 (+0.34), ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. to Attend November Healthcare Conferences
GlobeNewswire - Mon Nov 09, 7:00AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced that David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will attend the Stifel 2015 Healthcare Conference and that Brian Posner and Nino Pionati, Chief Strategy and Marketing Officer will attend the Canaccord Genuity Medical Technology & Diagnostics Forum.
ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Reports Third Quarter Financial Results
GlobeNewswire - Thu Nov 05, 6:00AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company", a provider of advanced wound care products, today announced financial results for the third quarter ended September 30, 2015.
ALQA: 1.14 (-0.01)
Four Penny Stocks To Watch Today, Friday, May 20
ACCESSWIRE - Fri May 20, 1:02PM CDT
MIAMI, FL / ACCESSWIRE / May 20, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch BBEP, RXMD, LNCO, andALQA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
LNCO: 0.12 (unch), BBEP: 0.13 (unch), ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. to Attend Craig-Hallum Institutional Investor Conference
GlobeNewswire - Mon May 16, 6:30AM CDT
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced that David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will attend the 13th Annual Craig-Hallum Institutional Investor Conference on Wednesday, June 1, 2016 at the Depot Renaissance Minneapolis Hotel in Minneapolis, MN. ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Reports First Quarter Financial Results
GlobeNewswire - Tue May 10, 6:07AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced financial results for the first quarter ended March 31, 2016. ALQA: 1.14 (-0.01)
Integra (IART) Beats on Q1 Earnings, Grows Organically
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:36PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 74 cents in the first quarter of 2016.
IART: 77.07 (+1.75), ANIP: 56.27 (+3.48), ANIK: 51.10 (+0.83), ALQA: 1.14 (-0.01)
Celgene Corporation (NASDAQ: CELG) CMO Joins MetaStat Inc (OTCQB: MTST) Board
ACCESSWIRE - Wed Apr 27, 9:26AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2016 / Development stage biotech company MetaStat Inc (OTCQB: MTST) just announced a high-profile, and potentially game changing addition to its board of directors. As of April 26, 2016, Jerome B. Zeldis, M.D., Ph.D, Chief Medical Officer of Celgene Corporation (NASDAQ:CELG) and Chief Executive Officer of Celgene Global Health, will join the Metastat board as its vice chairman. For a company the size of MetaStat, which had a market capitalization of a little over $3.42 million at last count, the addition of an industry professional with the standing of Zeldis is a validation of the potential of its lead diagnostics technology - something we will touch on in a little more detail shortly.
ALQA: 1.14 (-0.01), CELG: 100.66 (+1.43), CELGZ: 1.45 (+0.01)
Alliqua BioMedical, Inc. to Announce First Quarter of Fiscal Year 2016 Results on May 10th
GlobeNewswire - Tue Apr 26, 10:00AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced plans to release first quarter of fiscal year 2016 financial results before the market opens on May 10th. ALQA: 1.14 (-0.01)
New Strong Buy Stocks for April 26th
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:40AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AXE: 60.65 (+1.15), ANIP: 56.27 (+3.48), APRI: 0.47 (-0.01), ALQA: 1.14 (-0.01), FLWS: 8.43 (+0.10)
Alliqua BioMedical Presents at the Spring 2016 SAWC Meeting
GlobeNewswire - Tue Apr 12, 6:30AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, will present new cytokine profile data from the analyses of wound fluid and tissue biopsies taken from venous leg ulcers at the Spring 2016 Symposium on Advanced Wound Care, being held at the Georgia World Congress Center in Atlanta, Georgia from April 13 - 17. ALQA: 1.14 (-0.01)
Alliqua BioMedical to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Mar 30, 6:30AM CDT
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced that David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will attend the 15th Annual Needham Healthcare Conference in New York, New York. ALQA: 1.14 (-0.01)
Medical Products Companies Tap Into $50 Billion U.S. Government GSA Supply Program
ACCESSWIRE - Wed Mar 16, 7:30AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 16, 2016 / Last week, BioLargo, Inc. (OTC: BLGO), best known for the AOS Filter that has demonstrated the highest impact and lowest cost of any known water treatment technology, announced that the U.S. government had awarded them a five-year General Services Administration and VA Schedule supply contract, under schedule 65IIA for medical equipment and supplies. This contract award is significant because it opens up an important selling channel for the company's current odor and moisture control products as well as future products that will include its Advanced Wound Care Products when they are approved by the FDA. The GSA Schedules program is the premier acquisition vehicle in government with approximately $50 Billion a year in spending for a broad spectrum of products.
DSCI: 4.01 (+0.02), SNN: 34.65 (+0.38), VCEL: 2.29 (+0.06), ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Announces Participation in the Blue Cross Blue Shield Association's Evidence Street Pilot Program
GlobeNewswire - Tue Mar 15, 6:30AM CDT
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced that the Company is now a member of the Blue Cross Blue Shield Association's ("BCBSA" Evidence Street Pilot Program, a program designed to create uniformity in the exchange of clinical evidence used to establish BCBSA clinical guidelines. ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement Coverage for Biovance(R)
GlobeNewswire - Mon Mar 07, 6:30AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced that Biovance(R) Human Amniotic Membrane Allograft is now eligible for coverage in the geographic regions covered by Wisconsin Physicians Service ("WPS", a Medicare Administrative Contractor, or "MAC." ALQA: 1.14 (-0.01)
Alliqua BioMedical Announces Changes to Its Board of Directors
GlobeNewswire - Fri Feb 19, 6:30AM CST
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"
, today announced the appointment of Winston Kung to its Board of Directors. The Company also announced the departure of Perry Karsen from its Board of Directors. AMGN: 152.27 (+2.46), ALQA: 1.14 (-0.01), CELGZ: 1.45 (+0.01)
Alliqua BioMedical, Inc. to Announce Fourth Quarter and Fiscal Year 2015 Results on February 23rd
GlobeNewswire - Tue Feb 09, 6:30AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced plans to release fourth quarter and fiscal year 2015 financial results before the market opens on February 23rd. ALQA: 1.14 (-0.01)
Alliqua's UltraMIST(R) System Honored With GOOD DESIGN Award
GlobeNewswire - Thu Feb 04, 10:02AM CST
Alliqua BioMedical, Inc. (NASDAQ:ALQA) ("Alliqua" or "the Company"
, today announced that its UltraMIST Ultrasound Healing Therapy System received a GOOD DESIGN(R) Award. The GOOD DESIGN Awards are presented by The Chicago Athenaeum Museum of Architecture and Design and the Metropolitan Arts Press Ltd to the world's leading designers to acknowledge creativity, modernization, advancement and outstanding products that stretch the boundaries of average design. ALQA: 1.14 (-0.01)
Alliqua Biomedical Announces Partnership With Human Longevity Inc., Under Existing Licensing Agreement
GlobeNewswire - Thu Jan 28, 7:00AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced that following the completion of Human Longevity, Inc.'s ("HLI" planned purchase of LifebankUSA and other select assets from Celgene Cellular Therapeutics ("CCT", the Company will remain the exclusive commercial partner for the existing pipeline of human placental based products, including Biovance(R) Human Amniotic Membrane Allograft and CCT's connective tissue matrix product, which is pending commercial launch under its branded name, Interfyl(TM) Human Connective Tissue Matrix. ALQA: 1.14 (-0.01), CELGZ: 1.45 (+0.01)
Alliqua BioMedical Announces Agreement With HealthTrust
GlobeNewswire - Wed Jan 27, 6:30AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announces that it has signed a national group purchasing agreement with HealthTrust. The agreement, which became effective on Jan. 1, 2016, added Alliqua's Biovance(R) Human Amniotic Membrane Allograft ("Biovance" to HealthTrust's regenerative tissue wound care contracting category. ALQA: 1.14 (-0.01)
Direction of Market Influences - Research on Zion Oil and Gas, Alliqua Biomedical, MSB Financial and Profire Energy
ACCESSWIRE - Thu Dec 03, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Zion Oil and Gas Inc. (NASDAQ: ZN), Alliqua Biomedical Inc. (NASDAQ: ALQA), MSB Financial Corp. (NASDAQ: MSBF) and Profire Energy Inc. (NASDAQ: PFIE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ZN: 1.56 (+0.07), PFIE: 1.02 (+0.01), MSBF: 13.80 (+0.34), ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. to Attend November Healthcare Conferences
GlobeNewswire - Mon Nov 09, 7:00AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced that David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will attend the Stifel 2015 Healthcare Conference and that Brian Posner and Nino Pionati, Chief Strategy and Marketing Officer will attend the Canaccord Genuity Medical Technology & Diagnostics Forum. ALQA: 1.14 (-0.01)
Alliqua BioMedical, Inc. Reports Third Quarter Financial Results
GlobeNewswire - Thu Nov 05, 6:00AM CST
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"
, a provider of advanced wound care products, today announced financial results for the third quarter ended September 30, 2015. ALQA: 1.14 (-0.01)
